Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

about

Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

Item

http://www.wikidata.org/entity/Q47754588

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

@en

Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

@nl

type

Item

label

Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

@en

Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

@nl

prefLabel

Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

@en

Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

@nl

P1476

Metabolic changes in patients with prostate cancer during androgen deprivation therapy.

@en

P2093

Koji Mitsuzuka

http://www.w3.org/2001/XMLSchema#string

Yoichi Arai

http://www.w3.org/2001/XMLSchema#string

P2860

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy

Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade.

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Weight gain on androgen deprivation therapy: which patients are at highest risk?

Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.

Intermittent androgen suppression for rising PSA level after radiotherapy.

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

P304

45-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJU.13473

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29052905

http://www.w3.org/2001/XMLSchema#string